Find trials
Consejos para buscar

A Registry for the Scientific Study of Pulmonary Hypertension in the United States

Overview

Información sobre este estudio

The purpose of this study is to identify, characterize, and study a group of patients who have pulmonary hypertension, newly diagnosed in the current treatment era, when investigators can use the contributions of genomics and clinical imaging tests to further understand the disease. This registry should advance knowledge in the field both from a molecular (genomic and proteomic) and from a clinical phenotype standpoint.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Diagnosis of WHO Group I PAH (< 6 months) including the following subgroups
    • Pulmonary Arterial Hypertension (PAH)
      • Idiopathic PAH
      • Heritable PAH
        • BMPR2
        • ALK-1, ENG,SMAD9, CAV1, KCNK3
        • Unknown
      •  Drug and toxin induced
      • Associated with
        • Connective tissue disease
        • HIV infection
        • Portal hypertension
        • Congenital systemic to pulmonary shunts
    • Primary pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
  • Documentation of the following hemodynamic parameters by pulmonary artery catheterization
    • Mean pulmonary arterial pressure (PAPm) ≥ 25 mm Hg at rest
    • Pulmonary artery wedge pressure (PAWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mm Hg in the absence of mitral stenosis
    • Pulmonary vascular resistance (PVR) > 3 Wood Units
  • Patient has consented to participate in the NHLBI sponsored R24HL105333 National Biological Sample and Data Repository for PAH

Exclusion Criteria

  • Unwilling or unable to provide written consent for participation in the study
  • Has an underlying medical disorder (e.g. metastatic cancer) with an anticipated life expectancy less than 2 years
  • Does not meet inclusion criteria including
    • No documentation of hemodynamic criteria by pulmonary artery catheterization as outlined in the inclusion criteria
    • Meets the criteria for inclusion into WHO Diagnostic Groups II, III, IV or V

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Charles Burger, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20492629

Mayo Clinic Footer